|
NexImmune Raises 23 million doller to advance endogenous cellular immuno therapy into clinical development
NexImmune, an emerging leader in the field of antigen-directed immunotherapy, announced the closing of a Series A financing co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital ...
|
|
Adverum biotechnologies doses first patient in the ADVANCE phase 1/2 clinical trial of ADVM-043 for A1AT deficiency
Adverum Biotechnologies, Inc , a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced the dosing of the first patient in the ADVANCE Phase ...
|
|